Companies/US/NTLA

INTELLIA THERAPEUTICS, INC.

Last · NASDAQ$11.43-0.48 (-4.03%)close · yahoo · 17h ago
Vol 5.42M ≈ 61.99M
Market cap$1.60B140.1M sh
P/E · TTM-3.4fwd -4.5 · eps -3.35 · loss
Beta1.80vs S&P 500
Div yield0.00%annual · TTM
52w range
$7.95$28.25
Volume5.4Msession

Issuer

Legal nameINTELLIA THERAPEUTICS, INC.
HQUnited States (US)
ListingUS NTLA
ISINUS45826J1051
LEI5493002T5BCPE5DZC723
SectorHealthcare
IndustryDrugs (Biotechnology)
SIC2835
CurrencyUSD
Entity registrysec:0001652130
CIK0001652130
Websitewww.intelliatx.com
LinkedIn
Employees377
AddressIntellia Therapeutics, Inc. 40 Erie Street 02139, Cambridge +857 285 6200
Loading chart…

Upcoming earnings

1 event
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.79
Est. revenue
9.8M
View upcoming earnings →

Earnings transcripts

1 recent

Press & signals

3 of 6 recent
  • GlobeNewswire

    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • GlobeNewswire

    Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • GlobeNewswire

    Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

The rest of this company's wire — with summaries and source links — is part of Pro.

See plans

Documents

FormReporting forFiledFlags
4
2026-10-022026-10-060
8-K8-K: Regulation FD Disclosure
2026-09-082026-09-080
8-KCurrent Report (8-K)
—2026-09-040
8-K8-K: Results of Operations and Financial Condition
—2026-08-060
Showing 4 of 4 filings